Shanghai-based Huihe Healthcare, an interventional medical device maker for heart diseases, reportedly raised “hundreds of millions” of renminbi in Series C1 and C2 financing rounds. Guotai Junan Innovation Investment led the former while Shanghai Science and Technology Innovation Center Equity Investment Fund led the latter. The funding rounds included contributions from the Fund for Translating Research at G60 Sci-Tech Innovation Valley of Yangtze River Delta, Shanghai Songjiang State-Owned Assets Investment Management Group, Jiuting, and returning investors IDG Capital, Sherpa Healthcare Partners, and GF Capital.
Core Products and Commercialization
Huihe Healthcare’s core products, the K-Clip transcatheter tricuspid annulus repair system and C-Wave vascular shock wave system, are being readied for commercialization, having completed a confirmatory clinical study in China. Meanwhile, K-Clip is undergoing a CE confirmatory clinical study in Europe.-Fineline Info & Tech
